China Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Value Chain
Summary
This report analyzes the Chinese manufacturing industry, including company and facility trends, as well as drug approval and outsourcing trends. It assesses which foreign and domestic pharma manufacturing companies have the largest number of facilities in China, their manufacturing capabilities, which CMOs have secured the largest number of contracts for FDA and EMA approved products and quantifies the level of M&A activity for Chinese pharma
Scope
This report gives important, expert insight you won’t find in any other source. 13 tables and 22 figures throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives and strategic decision-makers: improves understanding of the pharma manufacturing industry in China and is a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Private equity investors: they can gain a deeper understanding of the Chinese CMO market and important insights for identifying potential targets
- Overview of the current pharma manufacturing landscape and how this will develop in future
- Detailed view of the geographic distribution of facilities
- Establishing which services are offered by Chinese facilities
- Analysis of M&A activity related to Chinese manufacturers
- About GlobalData
- Executive Summary
- Players
- Table Figure 1: Leading manufacturers with Chinese sites, 2022
- Trends
- Table Figure 2: Chinese manufacturing trends, 2022
- Table Injectable packaging trends, 2021
- Value Chain
- Table Figure 3: The contract manufacturing value chain
- Industry Analysis
- Introduction
- Table Figure 4: Map of China
- Geographic distribution of Chinese facilities
- Table Figure 5: FDA-approved Chinese pharma contract manufacturing site locations for all services
- Table FDA-approved Chinese pharma contract manufacturing site locations for all services
- Table Figure 6: FDA-approved Chinese pharma API chemical manufacturing site locations
- Table FDA-approved Chinese pharma API chemical manufacturing site locations
- Table Figure 7: FDA approved Chinese pharma commercial dose manufacturing site locations
- Table FDA-approved Chinese pharma commercial dose manufacturing site locations
- Manufacturing services at Chinese sites
- Table Figure 8: Services offered by Chinese facilities with FDA Approval, 2022
- Table Figure 9: Services offered by eastern Chinese facilities with FDA approval, 2022
- Table Figure 10: Services offered by southern Chinese facilities with FDA approval, 2022
- Table Figure 11: Services offered by northern Chinese facilities with FDA approval, 2022
- Table Figure 12: Services offered by western Chinese facilities with FDA approval, 2022
- Table China's facilities by service and location
- Specialized services: Containment and cell and gene therapy
- Table Figure 13: Containment substance manufacture offered by FDA-approved Chinese facilities, 2022
- Table Containment substance manufacture offered by FDA-approved Chinese facilities, 2022
- Table Chinese sites (any regulatory approval) with API biologics (cell, gene, vaccine, and virus) capabilities
- Companies with Chinese facilities
- Table Figure 14: Chinese companies by number of facilities with FDA-approval, 2022
- Table Figure 15: Headquarters of companies with Chinese facilities, 2022
- Table Headquarters of companies with Chinese facilities, by facility count, 2022
- Table Figure 16: Headquarters of companies with Chinese facilities.
- Contract service agreements at Chinese facilities
- Table Figure 17: API manufacturing facility locations for FDA- and EMA-approved drugs
- Table Figure 18: Dose manufacturing facility locations for FDA and EMA drugs
- Table Figure 19: Packaging facility locations for FDA- and EMA-approved drugs
- Molecule type, RoA, and outsourcing of Chinese-produced drugs
- Table Route of administration of drugs produced at FDA- and EMA-approved Chinese sites
- Table Molecule type of drugs Produced at FDA- and EMA-approved Chinese Sites
- Table Figure 20: Drugs with outsourcing relationships to Chinese sites
- Table Figure 21: Drugs by outsourcing company
- Chinese manufacturer deals activity
- Table Figure 22: CMO deals in China, 2019-22 (August)
- Foreign and domestic pharma investment
- Table Deals for Chinese CMOs with the highest deal value, January 2019 - August 2022
- What it means
- Chinese pharma manufacturing is too focused on small molecule API manufacturing and must diversify
- Potential barriers to growth
- Geographic divide for pharma manufacturing
- Introduction
- Companies
- Table Companies with FDA Approved Chinese Facilities, 2022
- Appendix
- Methodology
- Bibliography
- Primary research - key opinion leaders
- Further reading
- Table Further reading
- About the Authors
- Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook